Please login to the form below
Vitrakvi
This page shows the latest Vitrakvi news and features for those working in and with pharma, biotech and healthcare.
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
As Vitrakvi and Rozlytrek lead with their TA indications, the challenges faced by these therapies are wholly different to Keytruda. ... Vitrakvi and Rozlytrek target NTRK gene mutations and fusions in patients with locally advanced or metastatic disease
Latest news
-
Immuno-oncology, personalised medicine continues to drive pharma sector
A recent example of this issue is Bayer’s tumour-agnostic drug Vitrakvi (larotrectinib), which targets all solid tumours that display a NTRK gene fusion regardless of cancer type, but was ... Despite rejecting Vitrakvi, NICE said that it was in
-
Lilly will aim for one $1bn-$5bn deal per quarter in 2020
From that deal, it gained rights to NTRK-inhibitor Vitrakvi, which is FDA approved to treat any solid tumour that has a NTRK gene fusion.
-
NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
Last June, NHS England chief executive Simon Stevens (pictured left) announced that the health service wants to fast-track tumour-agnostic drugs, like Vitrakvi and Rozlytrek. ... However, in this most recent draft guidance, NICE deemed the current price
-
Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval
In the case of Vitrakvi, the drug targets tumours with a genetic variation known as neurotrophic tyrosine receptor kinase (NTRK). ... The list price for a month’s supply of Rozlytrek is just over $17, 000, compared to almost $33, 000 for Vitrakvi.
-
Lilly’s Levi Garraway will replace Sandra Horning as Roche CMO
The company has just picked up a new approval for targeted cancer drug Rozlytrek(entrectinib), a rival to Bayer’s Vitrakvi (larotrectinib), and for anti-CD79b antibody drug conjugate Polivy (polatuzumab
More from news
Approximately 4 fully matching, plus 12 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
9. Vitrakvi – a novel addition to the immune-oncology market. Earlier this year Merck &Co/MSD became the first company to secure approval for a ‘tissue agnostic’ drug when its ... Vitrakvi(larotrectinib) gained FDA approval in late November to
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Italy accelerates the path towards digital therapeutics implementation
- AstraZeneca’s mild combination asthma reliever approved in UK
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Results for Astellas’ non-hormonal menopause drug published in The Lancet
- Ketchum appoints Conor Nash as global chief financial officer and chief operating officer
- Kite reports positive three-year results for CAR T-cell therapy in rare blood cancer
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
